Table 1 Characteristics of RCTs
First auther | Year | Location | Sample size | Intervention(treatment/control) | Related outcomes | Allocation concealment |
|---|---|---|---|---|---|---|
Sudhindran S | 2001 | UK | 186 | 2 mg sublingual GTN 90/96 Control | A and B | ADEQUAT |
Wehrmann T | 2001 | Germany | 80 | 10 mg topical GTN 40/40 Control | A and B | NOT CLEAR |
Ghori A | 2002 | UK | 254 | 0.4-0.8 mg sublingualGTN128/126 Control | B | ADEQUATE |
Moretó M | 2003 | Spain | 144 | 15 mg transdermal GTN 71/73 Control | A and B | ADEQUATE |
Talwar A | 2005 | UK | 104 | 5 mg topical GTN52/52 Control | B | NOT CLEAR |
Kaffes AJ | 2006 | Australia | 318 | 5 mg transdermal GTN 155/163 Control | A and B | NOT CLEAR |
Beauchant M | 2008 | France | 208 | < mg intravenous GTN 105/103 Control | A and B | NOT CLEAR |
Nøjgaard C | 2009 | Norway | 806 | 15 mg transdermal GTN 401/405 Control | A and B | ADEQUATE |
Hao JY | 2009 | China | 74 | 5 mg sublingual GTN 38/36 Control | A | NOT CLEAR |
A: the outcome of PEP | B:the outcome of cannulation | |||||
The definition of the post-ERCP pancreatitis | ||||||
Sudhindran S | Acute pancreatitis was defined as a serum amylase level greater than 1000 (normal range 5-300) units/ml at 6 h in association with a visual analogue pain score of more than 5. | |||||
Wehrmann T | Pancreatitis, defined according to published recommendations by Cotton PB et al (1991). | |||||
Moretó M | Pancreatitis, defined according to published recommendations by Cotton PB et al (1991). | |||||
Kaffes AJ | Pancreatitis, defined according to published recommendations by Cotton PB et al (1991). | |||||
Beauchant M | Pancreatitis, defined according to published recommendations by Cotton PB et al (1991). | |||||
Nøjgaard C | Pancreatitis, defined according to published recommendations by Cotton PB et al (1991). | |||||
Hao JY | Post-ERCP pancreatitis could be defined as a disease with sustained pancreatitis symptoms (such as abdominal pain) and high-amylase value over the normal value after ERCP. | |||||